Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II first-in-human study of HP-002 in relapsed or refractory B-cell non-Hodgkin lymphoma
CTR20262270Phase 2Active
- Sponsor
- Shanghai Chaoyang Pharmaceutical
- Start
- Aug 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HP-002 in mature B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), sponsored by Shanghai Chaoyang Pharmaceutical. Started Aug 2026; status: active.
02
Drugs
HP-002
03
Conditions
mature B-cell lymphomachronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20262270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262270.